BioLife Solutions (BLFS) Expected to Announce Quarterly Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $22.22 million for the quarter. BioLife Solutions has set its FY 2025 guidance at EPS.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.32. The company had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the previous year, the business earned ($0.21) EPS. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLife Solutions Trading Up 2.7 %

BioLife Solutions stock traded up $0.67 during mid-day trading on Friday, hitting $25.27. 245,259 shares of the company's stock were exchanged, compared to its average volume of 376,968. The company's 50 day simple moving average is $24.02 and its 200-day simple moving average is $25.30. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.20 billion, a P/E ratio of -23.84 and a beta of 1.93. BioLife Solutions has a fifty-two week low of $17.15 and a fifty-two week high of $29.55.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BLFS. Northland Securities lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. StockNews.com lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. Finally, HC Wainwright increased their price objective on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, BioLife Solutions currently has an average rating of "Moderate Buy" and an average price target of $31.17.

Insiders Place Their Bets

In related news, EVP Aby J. Mathew sold 1,597 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $39,925.00. Following the completion of the transaction, the executive vice president now directly owns 260,601 shares of the company's stock, valued at approximately $6,515,025. This represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sarah Aebersold sold 5,771 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $130,770.86. Following the transaction, the insider now directly owns 80,094 shares of the company's stock, valued at $1,814,930.04. This trade represents a 6.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,127 shares of company stock valued at $1,676,533 in the last quarter. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.